Jyong Biotech Ltd. (MENS) Stock Price, Quote & News

Company Profile

Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Industry: Biotechnology

Sector: Healthcare

Phone: 886 2 2732 5205

Website: jyongbio.com

Address:

No. 95, Xintai 5th Road, 23F-3 Section 1 Xizhi District, New Taipei City, Taiwan

aquira Feb. 4 at 3:13 PM

$MENS furckkkkkk another day another ATL. Down 45% 20k

0 · Reply

Thegoat101 Feb. 3 at 8:55 PM

$MENS They keep pushing it down. then they will run it up 200%

0 · Reply

aquira Feb. 3 at 3:44 PM

$MENS i dont know. At this point I think we're headed to 1.5-2. Im already down 40% and 15k. FFS

0 · Reply

DavidMichery12345 Feb. 3 at 3:03 PM

$MENS Looking good. Just added $20,000 shares.

1 · Reply

liquidxx Feb. 2 at 7:27 PM

$MENS this should easily do a 200%+. Based on my Opinion and thoughts on this.

1 · Reply

liquidxx Feb. 2 at 7:22 PM

$MENS I’m thinking this will be next to run 200%+

0 · Reply

Torete8 Feb. 2 at 2:35 PM

$MENS 30 January 2026 Jyong Biotech Ltd. (NASDAQ:MENS) announced updated statistical analysis of its MCS-8 Phase II clinical trial, showing potential benefits beyond prostate cancer prevention. This clinical advance comes as the company faces important financial challenges, with data from InvestingPro showing that the stock is trading close to its 52-week low of $2.47, currently at $2.56, and has fallen more than 74% in the last year. The Taiwan-based biotechnology company reported that after two years of treatment, subjects who received MCS-8 showed a statistically significant reduction in total cholesterol levels compared to baseline. In addition, while the placebo group showed a statistically significant increase in serum lactate dehydrogenase (LDH) levels, such an increase was not observed in the MCS-8 group.

0 · Reply

superbodi Jan. 30 at 9:57 PM

$MENS honestly think we still might see 2.00. watching.

1 · Reply

aquira Jan. 30 at 3:41 PM

$MENS is it time to short this? I lost 10k already ffs

2 · Reply

Everythingisplanned Jan. 30 at 2:34 PM

$MENS Was definitely expecting a better reaction with such news 😂

0 · Reply

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Dec 19, 2025, 9:00 AM EST - 6 weeks ago

Jyong Biotech Responds to Share Price and Volume Movement

Dec 4, 2025, 8:30 AM EST - 2 months ago

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Nov 24, 2025, 8:30 AM EST - 2 months ago

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Nov 20, 2025, 8:30 AM EST - 2 months ago

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Sep 29, 2025, 8:30 AM EDT - 4 months ago

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Sep 18, 2025, 8:30 AM EDT - 4 months ago

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Sep 16, 2025, 8:18 AM EDT - 5 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Aug 22, 2025, 9:00 AM EDT - 5 months ago

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jul 26, 2025, 8:00 AM EDT - 6 months ago

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain

Jul 22, 2025, 10:40 AM EDT - 7 months ago

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

Jun 22, 2025, 4:20 PM EDT - 8 months ago

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

ALAB ARM CAI EGG IPO IPOS JCAP

Jun 18, 2025, 5:20 PM EDT - 8 months ago

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jun 16, 2025, 11:38 PM EDT - 8 months ago

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Feb 10, 2025, 3:42 PM EST - 1 year ago

Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle

Aug 18, 2023, 2:44 PM EDT - 2 years ago

Jyong Biotech Ltd. Begins U.S. IPO Rollout

Aug 17, 2023, 3:16 PM EDT - 2 years ago

Urinary disease biotech Jyong Biotech files for a $40 million US IPO

Aug 17, 2023, 1:40 PM EDT - 2 years ago

Jyong Biotech IPO Registration Document (F-1)

aquira Feb. 4 at 3:13 PM

$MENS furckkkkkk another day another ATL. Down 45% 20k

0 · Reply

Thegoat101 Feb. 3 at 8:55 PM

$MENS They keep pushing it down. then they will run it up 200%

0 · Reply

aquira Feb. 3 at 3:44 PM

$MENS i dont know. At this point I think we're headed to 1.5-2. Im already down 40% and 15k. FFS

0 · Reply

DavidMichery12345 Feb. 3 at 3:03 PM

$MENS Looking good. Just added $20,000 shares.

1 · Reply

liquidxx Feb. 2 at 7:27 PM

$MENS this should easily do a 200%+. Based on my Opinion and thoughts on this.

1 · Reply

liquidxx Feb. 2 at 7:22 PM

$MENS I’m thinking this will be next to run 200%+

0 · Reply

Torete8 Feb. 2 at 2:35 PM

0 · Reply

superbodi Jan. 30 at 9:57 PM

$MENS honestly think we still might see 2.00. watching.

1 · Reply

aquira Jan. 30 at 3:41 PM

$MENS is it time to short this? I lost 10k already ffs

2 · Reply

Everythingisplanned Jan. 30 at 2:34 PM

$MENS Was definitely expecting a better reaction with such news 😂

0 · Reply

Everythingisplanned Jan. 30 at 2:01 PM

$MENS https://www.globenewswire.com/news-release/2026/01/30/3229525/0/en/Jyong-Biotech-Subsidiary-Announces-Phase-II-Clinical-Data-on-Cholesterol-and-LDH-Indicators-for-MCS-8-PCP-Indicating-Potential-in-Prostate-Cancer-Prevention-and-Metabolic-Value.html

0 · Reply

Stock_Catcher Jan. 30 at 1:30 PM

$MENS Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

1 · Reply

aquira Jan. 29 at 6:44 PM

$MENS im really getting scared of the price action and the possibility that we'll go further down to 1.5-2. I'm alreasy 31% down as it is. Gawdd

2 · Reply

Everythingisplanned Jan. 29 at 5:40 PM

$MENS Let it flowwww!!!!

1 · Reply

Everythingisplanned Jan. 28 at 8:16 PM

$MENS any reason for the drop?

0 · Reply

aquira Jan. 28 at 5:49 PM

$MENS om my fuckkkeenn Gawd! 30% down!!!

0 · Reply

Xgurule Jan. 28 at 4:51 PM

$MENS 3months ago $50 a share? What happened to cause this drop?

0 · Reply

Everythingisplanned Jan. 28 at 3:58 PM

$MENS Need news!!

0 · Reply

aquira Jan. 28 at 3:45 PM

$MENS fuckkkkk im down 30%

1 · Reply

superbodi Jan. 28 at 3:02 PM

$MENS Looks like it might test 2.00-2.50 range.

1 · Reply

aquira Jan. 28 at 2:59 PM

$MENS are we fuck3eddd?? Im down 25% already

0 · Reply

Torete8 Jan. 28 at 2:42 PM

$MENS Buy

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	1,440,831
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A